VIRAL HEPATITIS IN ONCOLOGY PATIENTS: CLINICAL COURSE, DIAGNOSIS, AND MANAGEMENT

Background: Viral hepatitis, particularly hepatitis B (HBV) and hepatitis C (HCV), is a common comorbidity in cancer patients. Immunosuppressive conditions associated with malignancy or anticancer therapies increase the risk of viral reactivation, leading to liver dysfunction and potential interruption of cancer treatment. Aim: To review the clinical course, diagnostic strategies, and management approaches for viral hepatitis in oncology patients, emphasizing preventive antiviral interventions. Methods: Comprehensive review of current literature, international guidelines, and illustrative clinical cases related to HBV and HCV in cancer patients. Results: HBV reactivation can occur in up to 50% of high-risk patients receiving chemotherapy or immunosuppressive therapy without antiviral prophylaxis. HCV infection may accelerate liver fibrosis and compromise chemotherapy tolerance. Early screening, continuous monitoring, and prompt antiviral therapy are essential to maintain safe and effective cancer treatment.